Cargando…

Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare

PURPOSE: Spine surgeons have increasingly used intraoperative application of topical vancomycin powder (TVP) to prevent surgical site infections (SSIs). The goals of this study were to define the rate of pharmacological adverse reaction to TVP in young patients undergoing posterior spinal surgery an...

Descripción completa

Detalles Bibliográficos
Autores principales: DeFrancesco, C. J., Flynn, J. M., Smith, J. T., Luhmann, S. J., Sawyer, J. R., Glotzbecker, M., Pahys, J., Garg, S., Vitale, M., Farrington, D. M., Sturm, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone and Joint Surgery 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725766/
https://www.ncbi.nlm.nih.gov/pubmed/29263752
http://dx.doi.org/10.1302/1863-2548.11.170107
_version_ 1783285597170827264
author DeFrancesco, C. J.
Flynn, J. M.
Smith, J. T.
Luhmann, S. J.
Sawyer, J. R.
Glotzbecker, M.
Pahys, J.
Garg, S.
Vitale, M.
Farrington, D. M.
Sturm, P.
author_facet DeFrancesco, C. J.
Flynn, J. M.
Smith, J. T.
Luhmann, S. J.
Sawyer, J. R.
Glotzbecker, M.
Pahys, J.
Garg, S.
Vitale, M.
Farrington, D. M.
Sturm, P.
author_sort DeFrancesco, C. J.
collection PubMed
description PURPOSE: Spine surgeons have increasingly used intraoperative application of topical vancomycin powder (TVP) to prevent surgical site infections (SSIs). The goals of this study were to define the rate of pharmacological adverse reaction to TVP in young patients undergoing posterior spinal surgery and to summarise institutional variation in TVP dosing. METHODS: This retrospective observational study included ten spine centres in the United States and one in Europe. Patients with early onset scoliosis who underwent posterior spine surgery were eligible for inclusion. Age, weight, TVP dose and surgery type were recorded. Surgeries where patient age was > 12 years were excluded. Pharmacological adverse reactions were defined as clinical instances of Red Man Syndrome, rash, nephrotoxicity, proteinuria, hepatotoxicity or ototoxicity. The rate of pharmacological adverse reaction to TVP was calculated. Dosing practices were summarised. RESULTS: Patient age was in the range of seven months to 12 years (median ten years). Of 1398 observations, there was one possible pharmacological adverse reaction. This was in a ten-year-old, 20.4-kg female patient with neuromuscular sco-liosis undergoing growing rod implantation. She was dosed with 1500 mg of TVP and immediately developed a transient rash without systemic symptoms. This abated over minutes without any medical intervention. There were no other adverse reactions in the sample. The population rate of pharmacological adverse reaction was 0.072% (95% confidence interval 0 to 0.4). Significant variability in dosing practices existed between centres. CONCLUSION: Pharmacological adverse reactions to TVP are rare. Future work may establish evidence-based guidelines for TVP dosing based on patient weight and other variables.
format Online
Article
Text
id pubmed-5725766
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The British Editorial Society of Bone and Joint Surgery
record_format MEDLINE/PubMed
spelling pubmed-57257662017-12-20 Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare DeFrancesco, C. J. Flynn, J. M. Smith, J. T. Luhmann, S. J. Sawyer, J. R. Glotzbecker, M. Pahys, J. Garg, S. Vitale, M. Farrington, D. M. Sturm, P. J Child Orthop Original Clinical Articles PURPOSE: Spine surgeons have increasingly used intraoperative application of topical vancomycin powder (TVP) to prevent surgical site infections (SSIs). The goals of this study were to define the rate of pharmacological adverse reaction to TVP in young patients undergoing posterior spinal surgery and to summarise institutional variation in TVP dosing. METHODS: This retrospective observational study included ten spine centres in the United States and one in Europe. Patients with early onset scoliosis who underwent posterior spine surgery were eligible for inclusion. Age, weight, TVP dose and surgery type were recorded. Surgeries where patient age was > 12 years were excluded. Pharmacological adverse reactions were defined as clinical instances of Red Man Syndrome, rash, nephrotoxicity, proteinuria, hepatotoxicity or ototoxicity. The rate of pharmacological adverse reaction to TVP was calculated. Dosing practices were summarised. RESULTS: Patient age was in the range of seven months to 12 years (median ten years). Of 1398 observations, there was one possible pharmacological adverse reaction. This was in a ten-year-old, 20.4-kg female patient with neuromuscular sco-liosis undergoing growing rod implantation. She was dosed with 1500 mg of TVP and immediately developed a transient rash without systemic symptoms. This abated over minutes without any medical intervention. There were no other adverse reactions in the sample. The population rate of pharmacological adverse reaction was 0.072% (95% confidence interval 0 to 0.4). Significant variability in dosing practices existed between centres. CONCLUSION: Pharmacological adverse reactions to TVP are rare. Future work may establish evidence-based guidelines for TVP dosing based on patient weight and other variables. The British Editorial Society of Bone and Joint Surgery 2017-12-01 /pmc/articles/PMC5725766/ /pubmed/29263752 http://dx.doi.org/10.1302/1863-2548.11.170107 Text en Copyright © 2017, The British Editorial Society of Bone and Joint Surgery: All rights reserved http://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.
spellingShingle Original Clinical Articles
DeFrancesco, C. J.
Flynn, J. M.
Smith, J. T.
Luhmann, S. J.
Sawyer, J. R.
Glotzbecker, M.
Pahys, J.
Garg, S.
Vitale, M.
Farrington, D. M.
Sturm, P.
Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
title Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
title_full Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
title_fullStr Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
title_full_unstemmed Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
title_short Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
title_sort clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare
topic Original Clinical Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725766/
https://www.ncbi.nlm.nih.gov/pubmed/29263752
http://dx.doi.org/10.1302/1863-2548.11.170107
work_keys_str_mv AT defrancescocj clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT flynnjm clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT smithjt clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT luhmannsj clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT sawyerjr clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT glotzbeckerm clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT pahysj clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT gargs clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT vitalem clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT farringtondm clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT sturmp clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare
AT clinicallyapparentadversereactionstointrawoundvancomycinpowderinearlyonsetscoliosisarerare